Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 1;30(6):273-279.
doi: 10.1097/MED.0000000000000835. Epub 2023 Sep 5.

Glucagon-like peptide-1 receptor agonists and safety in the preconception period

Evelyn Minis  1 , Fatima Cody Stanford  2 , Shruthi Mahalingaiah  1   3
Affiliations
Review

Glucagon-like peptide-1 receptor agonists and safety in the preconception period

Evelyn Minis et al. Curr Opin Endocrinol Diabetes Obes. .

Abstract

Purpose of review: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are becoming increasingly popular for the treatment of type II diabetes and obesity. Body mass index (BMI) thresholds at in vitro fertilization (IVF) clinics may further drive the use of these medications before infertility treatment. However, most clinical guidance regarding optimal time to discontinue these medications prior to conception is based on animal data. The purpose of this review was to evaluate the literature for evidence-based guidance regarding the preconception use of GLP-1 RA.

Recent findings: 16 articles were found in our PubMed search, 10 were excluded as they were reviews or reported on animal data. Included were 3 case reports detailing pregnancy outcomes in individual patients that conceived while on a GLP-1 RA and 2 randomized controlled trials (RCTs) and a follow-up study to one of the RCTs that reported on patients randomized to GLP-1 RA or metformin prior to conception. No adverse pregnancy or neonatal outcomes were reported.

Summary: There are limited data from human studies to guide decision-making regarding timing of discontinuation of GLP-1 RA before conception. Studies focused on pregnancy and neonatal outcomes would provide additional information regarding a safe washout period. Based on the available literature a 4-week washout period prior to attempting conception may be considered for the agents reviewed in this publication.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

There are no conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
Flow diagram of articles reviewed, excluded and included.
See this image and copyright information in PMC

References

    1. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, no. 360. Hyattsville, MD: National Center for Health Statistics; 2020. - PubMed
    1. Mendola ND, Chen T-C, Gu Q, et al. Prevalence of total, diagnosed, and undiagnosed diabetes among adults: United States, 2013–2016. NCHS Data Brief, no. 319. Hyattsville, MD: National Center for Health Statistics; 2018. - PubMed
    1. Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab 2020; 105:e2695–e2709. - PMC - PubMed
    1. Ogunwole SM, Zera CA, Stanford FC. Obesity management in women of reproductive age. JAMA 2021; 325:433–434. - PMC - PubMed
    1. Talmor A, Dunphy B. Female obesity and infertility. Best Pract Res Clin Obstet Gynaecol 2015; 29:498–506. - PubMed

Publication types